What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His primary scientific interests are in Cancer research, Cancer, Carcinogenesis, Immunology and Cyclin D1.
His Cancer research research is multidisciplinary, relying on both Cell, Pancreatic cancer, Oncogene, SOX2 and Metastasis.
His Pancreatic cancer study integrates concerns from other disciplines, such as KRAS, Pancreas and Adenocarcinoma.
The Cancer study combines topics in areas such as Gene duplication and Germline mutation.
His Carcinogenesis study incorporates themes from Gene family, SCNA, Functional genomics, DNA mismatch repair and Gene dosage.
His Immunology research includes elements of Macrophage, Stem cell and Adult stem cell.
His most cited work include:
- The landscape of somatic copy-number alteration across human cancers (2544 citations)
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice (1543 citations)
- EMT and Dissemination Precede Pancreatic Tumor Formation (1303 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Cancer research, Internal medicine, Cell biology, Cancer and Pathology.
The various areas that Anil K. Rustgi examines in his Cancer research study include Pancreatic cancer, Carcinogenesis, Immunology, Metastasis and Cyclin D1.
In his study, Adenocarcinoma is strongly linked to Pancreas, which falls under the umbrella field of Pancreatic cancer.
His Internal medicine research includes themes of Gastroenterology, Endocrinology and Oncology.
The concepts of his Cell biology study are interwoven with issues in Cell, Epithelium and Cellular differentiation.
His study with Cancer involves better knowledge in Genetics.
He most often published in these fields:
- Cancer research (46.06%)
- Internal medicine (15.96%)
- Cell biology (16.33%)
What were the highlights of his more recent work (between 2015-2021)?
- Cancer research (46.06%)
- Internal medicine (15.96%)
- Pancreatic cancer (11.01%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Internal medicine, Pancreatic cancer, Cancer and Cell biology.
His Cancer research research incorporates themes from Carcinogenesis, KRAS, Metastasis and Immunology.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Oncology.
His Pancreatic cancer research is multidisciplinary, incorporating perspectives in Diabetes mellitus and Gene, Gene isoform.
His Cancer study is associated with Genetics.
His work is dedicated to discovering how Cell biology, Mrna binding are connected with Intestinal homeostasis and other disciplines.
Between 2015 and 2021, his most popular works were:
- Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients (263 citations)
- Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer (160 citations)
- Squamous Cell Cancers: A Unified Perspective on Biology and Genetics (119 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Anil K. Rustgi focuses on Cancer research, Cancer, Immunology, Pancreatic cancer and KRAS.
Anil K. Rustgi studies Cancer research, namely Tumor microenvironment.
His Cancer research integrates issues from Metaplasia, Dysplasia and Pathology.
His research integrates issues of Cancer stem cell, Cytotoxic T cell, Cell cycle and Epidermal growth factor receptor in his study of Immunology.
His studies in Pancreatic cancer integrate themes in fields like Diabetes mellitus, Gene isoform, Pancreatitis and Candidate gene.
His study looks at the relationship between KRAS and fields such as Lung cancer, as well as how they intersect with chemical problems.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
